These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16679728)

  • 41. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
    Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
    Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM; Stolz B; Albert R; Ruser G; Briner U; Mäcke HR; Bruns C
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of radioactive somatostatin and its analogues in the control of tumor growth.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
    Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor.
    Bernhardt P; Kölby L; Johanson V; Benjegård SA; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2001 Jan; 28(1):67-73. PubMed ID: 11182566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study].
    Inoue T; Ootake H; Hirano T; Tomiyoshi K; Endo K; Tanaka K; Shimizu N; Saito T
    Kaku Igaku; 1995 May; 32(5):511-21. PubMed ID: 7596072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
    Brabander T; Teunissen J; Kwekkeboom D
    Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
    Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
    Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
    Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide.
    Forssell-Aronsson E; Bernhardt P; Nilsson O; Tisell LE; Wängberg B; Ahlman H
    Acta Oncol; 2004; 43(5):436-42. PubMed ID: 15360047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH; Krenning EP; Reubi JC; Breeman WA; Setyono-Han B; de Jong M; Kooij PP; Bruns C; van Hagen PM; Marbach P
    Life Sci; 1991; 49(22):1593-601. PubMed ID: 1658516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
    Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
    Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical relevance of 111In-octreotide scans in CNS tumors.
    Sciuto R; Ferraironi A; Semprebene A; Occhipinti E; Mastrostefano R; Crecco M; Mottolese M; Maini CL
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):101-3. PubMed ID: 9002762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
    Slooter GD; Aalbers AG; Breeman WA; Hiemstra CA; Marquet RL; Krenning EP; van Eijck CH
    J Nucl Med; 2002 Dec; 43(12):1681-7. PubMed ID: 12468520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide.
    Verwijnen SM; Krenning EP; Valkema R; Huijmans JG; de Jong M
    J Nucl Med; 2005 Dec; 46(12):2057-60. PubMed ID: 16330570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.
    Kratochwil C; Mavriopoulou E; Rath D; Afshar-Oromieh A; Apostolopoulos D; Haufe S; Mier W; Haberkorn U; Giesel FL
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):116-20. PubMed ID: 24382404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.